HOME PAGE
COMPANY PROFILE
SCIENCE
PIPELINES
PARTNERSHIP
NEWS
CAREERS
CONTACT US
中文
EN
菜单
HOME PAGE
COMPANY PROFILE
Company Introduction
Company History
Management Team
NEWS
Neurophth News
SCIENCE
Gene Therapy
R&D Platforms
CMC Platforms
PIPELINES
Pipeline
Leber’s Hereditary Optic Neuropathy
Autosomal Dominant Optic Atrophy
Optic Nerve Injury
Vascular Retinopathy
CAREERS
Employee development
Working at Neurophth
Compensation & Benefits
CONTACT US
PARTNERSHIP
中文
EN
NEWS
2023-09-18
Special interview with Chinese and international top neuro-ophthalmologists on LHON Awareness Day
2023-09-05
Neurophth Secures Australian Approval for Ophthalmic Gene Therapy
2023-08-17
Neurophth Announces First Patient Dosed in Phase I/II Clinical Trial of Second Gene Therapy
2023-06-08
Special interview with Dr. Marcela Ciccioli
2023-04-15
Neurophth Announces IND Approval by the NMPA for Second Gene Therapy NFS-02 (rAAV2-ND1)
2023-04-06
Neurophth's Gene Therapy NR082 Completes Initiation of Multiple Clinical Research Centers in U.S.
2023-03-08
Maltese Patient Received World's First ND1-LHON Gene Therapy Injection Donated by Neurophth in China
2023-02-22
Commercialization of Gene Therapy is coming soon: Neurophth Completes Patient Enrollment for Phase III clinical trial for the gene therapy treatment of LHON
2022-12-21
1st LHON INTERNATIONAL FORUM
1
2
3
4
下一页